

INDEX: Volume IV

A

- absorption
 - drug
 - malnutrition 291
 - interference with 265
- acetylamino-biphenyl 209
- acetylamino-fluorene
 - ring-hydroxylated derivatives 222
- acetylamino-fluorene 217
- acetylation
 - isolated hepatocytes 102
- activated charcoal 267
- acyclic hydroxylation
 - isolated hepatocytes 101
- adverse reactions
 - dietary excess of nutrients 291
- age
 - as predisposing factor in methoxyflurane nephrotoxicity 57
- alcohol cleavage
 - isolated hepatocytes 102
- alcoholism
 - deficiency of pyridoxal phosphate 294
- alcohols 147
- aliphatic halogenated xenobiotics
 - carcinogenicity 2
 - specific covalent binding and toxicity, 2
- amiloride 275
- aminobiphenyl
 - N-acyl derivatives 209
 - ring-hydroxylated derivatives 208
- aminobiphenyl 206
- amino-fluorene
 - N-acyl derivatives 217
 - ring-hydroxylated derivatives 216
- amino-fluorene 213
- amiodarone 275
- amphotericin 278
- anaesthetics 49
- androgen receptors
 - pyridoxal phosphate 314

- aniline 199
- anorectic agents
 - drug interactions 301
- antacids 265
- anti-convulsants 147
- anti-fungals 147
- anti-histamines 147
- anti-inflammatorys 147
- antianginal agents
 - pyridoxal phosphate 306
- antiarrhythmics 275
- antiasthmatics
 - pyridoxal phosphate 306
- antibiotics 147
- antidepressants
 - pyridoxal phosphate 306
- antihistamines
 - pyridoxal phosphate 306
- antihypertensives
 - antivitamin B6 effects 306
- antimicrobials
 - pyridoxal phosphate 306
- antiviral substances
 - pyridoxal phosphate 306
- aromatic amides 147
- aromatic hydroxylation
 - isolated hepatocytes 101
- arylamines
 - carcinogenicity
 - structure-activity relationships 197
 - correlation between the
 - ferrihemoglobinogenic 171
 - differences in the ferrihemoglobin-forming 171
 - monocyclic_
 - carcinogenicity
 - aniline 199
 - chloroaniline 203
 - dichloroaniline 204
 - phenetidine 201
 - polycyclic
 - carcinogenicity
 - acetylaminobiphenyl 209
 - acetylaminofluorene 217

- aminobiphenyl 206
- aminofluorene 212
- N-acyl-2-fluorenylhydroxylamines 219
- N-acyl-4-biphenylhydroxylamines 210
- N-hydroxy-2-acetylaminofluorene 219
- N-hydroxy-2-aminofluorene 213
- N-hydroxy-4-acetylaminobiphenyl 210
- N-hydroxy-4-aminobiphenyl 207
- nitrobiphenyl 208
- nitrofluorene 215
- nitrosobiphenyl 207
- nitrosofluorene 214
- O-acyl and glucuronyl derivatives of
N-hydroxy-4-acetylaminobiphenyl 211
- O-acyl and glucuronyl derivatives of
N-hydroxy-2-acetylaminofluorene and
other N-acyl-2-fluorenylhydroxyl-
amines 223
- arylamines 175
- arylhydroxylamines
 - ferrihemoglobin-formation
 - experiments in vitro 189
 - experiments in vivo 192
 - hemoglobin-oxidation 188
- arylhydroxylamines 179
- B
- beta-blockers 279
- binding
 - drug
 - malnutrition 291
- biotransformation
 - drug
 - malnutrition 291
 - phase 292
 - phase II 292
- bowel motility
 - altered 267
- C
- calcium salts
 - digitalis glycosides 278
- cancer chemotherapy
 - pyridoxal phosphate 306

- carbon tetrachloride
 - toxicity 2,8
- carcinogenicities
 - differences in the ferrihemoglobin forming capabilities and, 171
- carcinogenicity
 - arylamines
 - structure activity relationships 197
 - reactive metabolic intermediates 31, 2
 - specific covalent binding 31, 2
- cardiac drugs 264
- Chinese restaurant syndrome 306
- chloroaniline 203
- chloroform
 - toxicity 6, 2
- cholestyramine 266
- cimetidine 268
- cis-dichloroethylene 26, 2
- clearance
 - altered
 - digitalis glycosides 269
- colestipol 266
- contraceptives
 - steroid 310
- contragestational agents
 - non-hormonal
 - contragestational profile 243
 - influence of first pass metabolism 253
 - pharmacodynamic-pharmacokinetic relationships 237
 - pharmacokinetics-activity relationships 245
 - structure-activity relationships 238
 - non-prostaglandin 238
 - phenyl triazole isoindoles 238
- covalent binding
 - carcinogenicity 31
 - halothane 71
 - reactive metabolites alkylating nucleophilic sites 2
 - specific covalent binding and toxicity of aliphatic halogenated xenobiotics 2

- toxicity 32
- cytochrome P-450
 - biosynthesis of
 - directed by rat liver messenger RNA 145
 - catalysed reactions 124
 - covalent binding 10,15,18
 - gene structures 155
 - halothane biotransformation 70
 - messenger RNA
 - in vitro translation and purification 150
 - multiple enzyme forms 154
 - multiple forms
 - characteristics 128
 - human liver microsomes 142
 - mouse liver microsomes 141
 - rabbit liver and lung microsomes 137
 - rat liver microsomes 129
 - needed nutrients 292
 - nomenclature 128
 - polymorphism
 - halothane metabolism 87
 - protein needs 292
 - regulation of at level of messenger RNA
 - transcription 155
 - xenobiotic inducers of
 - chemicals 147
 - drugs 147
- cytochrome P-450 57
- cytochrome P-450
 - induction of by xenobiotics
 - molecular events following 145
- cytotoxic drugs 267
- acetylation
 - isolated hepatocytes 102
- 2,3,7,8-tetrachlorodibenzo-p-dioxins 147
- 1,2-dibromo-3-chloropropane
 - toxicity 16, 2
- 1,2-dibromoethane
 - toxicity 11, 2
- 2-chloroaniline 204
- 1,2-dichloroethane

- toxicity 11, 2
- digitalis glycosides
 - altered bowel motility
 - metoclopramide 267
 - propantheline 267
 - altered distribution and clearance
 - amiloride 275
 - nifedipine 275
 - quinidine 269
 - spironolactone 275
 - triamterene 275
 - vasodilators 276
 - verapamil 274
 - altered metabolism
 - cimetidine 268
 - phenobarbital 268
 - phenylbutazone 268
 - phenytoin 268
 - quinidine 268
 - rifampin 268
 - spironolactone 268
 - altered protein binding
 - heparin 268
 - serum albumin 267
 - altered urinary excretion
 - furosemide 269
 - loop diuretics 269
- drug interactions involving 263
- interference with absorption
 - activated charcoal 267
 - antacids 265
 - antibiotics 267
 - cholestyramine 265
 - colestipol 266
 - cytotoxic agents 267
 - fiber 267
 - kaolin 265
 - neomycin 266
 - pectin 265
 - phenytoin 267
 - sulphasalazine 266
- pharmacodynamic interactions
 - calcium salts 278

- halothane 279
 - lidocaine 279
 - phenytoin 279
 - succinylcholine 280
- digitalis glycosides 264
- digitoxin 264
- digoxin 264
- disease states
 - drug efficacy 295
- disopyramide 275
- distribution
 - altered digitalis glycosides 269
 - drug
 - malnutrition 291
- diuretics 277
- DNA
 - recombinant DNA studies 153
- DNA alkylation 31, 2
- dose
 - as predisposing factor in methoxyflurane
 - nephrotoxicity 54
 - drug detoxification
 - nutrients 291
 - drug efficacy
 - disease states 295
 - drug oxidations
 - species differences in 128
 - drugs
 - nullification of therapeutic effects
 - of by vitamins 298

E

- endogenous depression
 - pyridoxal phosphate 310
- enflurane
 - enzyme induction 64
 - hepatotoxicity 65
 - metabolism 59
 - obesity 64
 - renal toxicity 59
 - side effects 66
- enzyme induction
 - as predisposing factor in methoxyflurane
 - nephrotoxicity 57

- enflurane 64
- epoxidation
 - isolated hepatocytes 101
- ester cleavage
 - isolated hepatocytes 102
- estrogen receptors
 - pyridoxal phosphate 314
- excretion
 - drug
 - malnutrition 291

F

- ferrihemoglobin-forming capabilities
 - differences in the 171
- fiber 267
- flavones 147
- food anti-oxidants 147

G

GABA

- recognition sites
 - pyridoxal phosphate 315
- genetic factors
 - as predisposing factor in methoxyflurane nephrotoxicity 54
- genetic susceptibility
 - role of in halothane hepatotoxicity 79
- glucocorticoid receptors
 - pyridoxal phosphate 312
- glucuronidation
 - isolated hepatocytes 102
- glutathione conjugation
 - isolated hepatocytes 102
- glycine conjugation
 - isolated hepatocytes 102

H

haloalkanes

- carbon tetrachloride 8, 2
- chloroform 6, 2
- dibromo-3-chloropropane 16
- dibromoethane 11, 2
- dichloroethane 11, 2
- methylene chloride 4, 2

- reactive metabolites 4, 2
- toxicity 4, 2
- trichloroethane 14, 2
- haloalkenes
 - cis-dichloroethylene 26, 2
 - perchloroethylene 29, 2
 - reactive metabolites 18, 2
 - toxicity 18, 2
 - trans-dichloroethylene 26, 2
 - trichloroethylene 27, 2
 - vinyl bromide 20, 2
 - vinyl chloride 20, 2
 - vinyl fluoride 20, 2
 - vinylidene chloride 24, 2
 - vinylidene fluoride 24, 2
- haloethanes
 - biotransformation 18
- halogenated aliphatic hydrocarbons
 - toxicity
 - reactive, 2
- halogenated aliphatic xenobiotics
 - mutagenicity
 - short term assays 2
- halogenated biphenyls 147
- halothane
 - covalent binding
 - 71
 - hepatotoxicity
 - applicability of animal models
 - criteria 76
 - genetic susceptibility 79
 - multiple exposures 79
 - pathology of the lesion 84
 - radiation therapy 85
 - role of immune response 81
 - role of metabolism in hepatotoxicity 77
 - routes and extent of halothane
 - biotransformation 77
 - sex differences 79
 - hepatotoxicity 72
 - hepatotoxicity of end products of
 - biotransformation 73
 - lipid peroxidation 71

- metabolism
 - biotransformation
 - pathways 70
 - metabolism 68
 - renal toxicity 72
 - role of biotransformation in hepatotoxicity
 - animal models 73
- heparin 269
- hepatocytes
 - isolated 99
- hepatotoxicity
 - enflurane 59
 - halothane 72
 - isoflurane 68
 - methoxyflurane 58
- hereditary disorders
 - efficacy of vitamin B6 295
- hydrocarbons
 - halogenated short chained
 - chemical and physical properties 2
- hydroxychloroquine 274
- hyperkalemia
 - drugs inducing
 - digitalis glycosides 278
- hypnotics 147
- hypokalemia
 - drugs inducing
 - digitalis glycosides 277
- hypolipidaemics 147
- I
- immune response
 - role of in halothane hepatotoxicity 81
- immunosuppressive medications
 - pyridoxal phosphate 306
- indoles 147
- insecticides 147
- isoflurane
 - hepatotoxicity 68
 - metabolism 66
 - renal toxicity 68
- isoindoles
 - 2-phenyl-triazole

- contragestational agents 238
- isolated hepatocytes
 - balance of Phase I to Phase II
 - metabolism 100,111
 - metabolism of drugs by 99
 - reactions studied in
 - acetylation 102
 - acyclic hydroxytlation 101
 - alcohol oxidation 102
 - aromatic hydroxylation 101
 - deacetylation 102
 - epoxidation 101
 - ester cleavage 102
 - glucuronidation 102
 - glutathione conjugation 102
 - glycine conjugation 102
 - N-dealkylation 101
 - N-hydroxylation 101
 - O-dealkylation 101
 - sulphation 102
 - relation of metabolism to toxicity 100, 1
 - xenobiotic metabolism
 - species and organ differences 104
- isoniazid
 - neurotoxicity 304
 - vitamin B6 304
- isoguinolines
 - dehydro
 - contragestational agents 238
- K
- kaolin 265
- L
- lipid peroxidation
 - halothane 71
- lithium 277
- M
- malnutrition
 - drug absorption 291
 - drug binding 291
 - drug biotransformation 291
 - drug distribution 291

- drug excretion 291
- megavitamins 298
- messenger RNA's
 - species differences in cytochromes P-450 123
- metabolism
 - altered
 - digitalis glycosides 268
 - enflurane 59
 - halothane 68
 - isoflurane 66
 - methoxyflurane 51
 - volatile anaesthetics 50
- metabolites
 - active
 - xenobiotic toxicity 109
- methoxyflurane
 - hepatotoxicity 58
 - metabolism 51
 - nephrotoxicity 54
 - renal toxicity 53
- methylene chloride
 - toxicity 4, 2
- methylenedioxyphenyls 147
- metoclopramide 267
- mexiletine 275
- microsomes
 - human liver
 - multiple forms of cytochrome P-450 142
 - mouse liver
 - multiple forms of cytochrome P-450 141
 - rabbit liver and lung
 - multiple forms of cytochrome P-450 137, 1
 - rat liver
 - multiple forms of cytochrome P-450 129, 1
- molecular events
 - following induction of hepatic cytochrome P-450 145
- monosodium glutamate
 - pyridoxal phosphate 306
- multiple exposure
 - role of in halothane hepatotoxicity 79
- mutagenicity

toxic metabolites produced by cytochrome
P-450 154

N

- N-acyl-2-fluorenylhydroxylamines 219
- N-acyl-2-fluorenylhydroxylamines 223
- N-acyl-4-biphenylhydroxylamines 210
- N-acylarylamines
 - differences in the ferrihemoglobin-forming capabilities and carcinogenicities 171
- N-acylarylamines 181
- N-arylacetohydroxamic acids
 - hemoglobin-oxidation 188
- N-arylacetohydroxamic acids 185
- N-dealkylation
 - isolated hepatocytes 101
- N-hydroxy-2-acetylaminofluorene
 - O-acyl and glucuronyl derivatives 223
- N-hydroxy-2-acetylaminofluorene 219
- N-hydroxy-2-aminofluorene 213
- N-hydroxy-4-acetylaminobiphenyl
 - O-acyl and glucuronyl derivatives 211
- N-hydroxy-4-acetylaminobiphenyl 210
- N-hydroxy-4-aminobiphenyl 207
- N-hydroxylation
 - isolated hepatocytes 101
- narcotic analgesics 147
- neomycin 266
- nephrotoxicity
 - methoxyflurane
 - predisposing factors
 - age 57
 - dose 54
 - enzyme induction 57
 - genetic factors 54
 - obesity 58
- nervous system activity
 - drugs altering
 - digitalis glycosides 278
- neuroendocrinology
 - pyridoxal phosphate 311
- nifedipine 275
- nitrobiphenyl 207

- nitrofluorene 215
- nitrosobiphenyl 207
- nitrosofluorene 214
- nutrient
 - excess
 - adverse reactions 291
- nutrients
 - drug detoxification 291
 - nutritional status and drug efficacy 293

O

- O-dealkylation
 - isolated hepatocytes 101
- obesity
 - as predisposing factor in methoxyflurane nephrotoxicity 58
 - enflurane 64
- orectic agents
 - drug interactions 301
- ouabain 264, 1

P

- para-aminosalicylic acid 266
- pectin 265
- penicillamine
 - vitamin B6 and 307
- perchloroethylene 29, 2
- phase I and phase II reactions
 - balance of in xenobiotic metabolism 111
- phenetidine 201
- phenobarbital 268
- phenytoin 267
- picolinic acid
 - vitamin B6 308
- polycyclic aromatic hydrocarbons 147
- procainamide 275
- progesterone receptors
 - pyridoxal phosphate 314
- propantheline 267
- prostaglandin
 - non-prostaglandin contragestational agents 238
- protein binding
 - altered 267

- protein deficiency
 - dietary
 - drug metabolizing enzymes 293
 - drug toxicity 293
- psychotropics 147
- psyllium hydrophilic mucilloid 267
- pyridixal phosphate
 - vitamin B6 and penicillamine 307
- pyridoxal phosphate
 - anorectic and orectic agents in drug interactions 301
 - antivitamin B6 effects of compounds
 - antivirals 306
 - bioavailability of other drugs 291
 - deamination 290
 - decarboxylation 290
 - desulphydration reactions 290
 - drug efficacy and disease states 295
 - drug efficacy and nutritional status 294
 - endogenous depression and steroid contraceptives 310
 - GABA recognition sites 315
 - hereditary disorders 295
 - malnutrition
 - drug detoxification 291
 - metabolism
 - amino acids 290
 - carbohydrates 290
 - coenzymes 290
 - hormones 290
 - lipids 290
 - nucleic acids 290
 - proteins 290
 - neurobiology 290
 - neuroendocrinology 311
 - neurotransmitters 290
 - nullification of therapeutic effects of drugs by 298
 - nutrients and drug detoxification 291
 - pharmacokinetics 302
 - polyamines 290

- protein deficiency 291
- racemization 290
- steroid receptor sites
 - androgen receptors 314
 - glucocorticoid receptors 312
 - progesterone receptors 314
 - strogen receptors 314
- synthesis 301
- transamination 290
- vitamin B6 and monosodium glutamate metabolism 304
- vitamin B6 and picolinic acid in zinc absorption 308
- vitamin B6 efficacy in hereditary disorders 295
- vitamin B6 transport and metabolism 302
- pyridoxal phosphate-drug interactions 289
- pyridoxine vitamers
 - pharmacokinetics 301

Q

- quinidine-digoxin interaction 269
- quinine 274

R

- radiation therapy
 - halothane hepatotoxicity 85
- renal toxicity
 - enflurane 59
 - halothane 72
 - isoflurane 68
 - methoxyflurane 53
- reserpine 279
- respiratory stimulants 147
- rifampin 268

S

- sedatives 147
- serum albumin 268
- sex differences
 - role of in halothane hepatotoxicity 79
- species differences
 - cytochromes P-450 and corresponding messenger RNA 123

- spironolactone 268
- steroid contraceptives
 - pyridoxal phosphate 310
- steroid receptor sites
 - pyridoxal phosphate 312
- steroids 147
- structure activity relationships
 - arylamines
 - carcinogenicity 197
- structure-activity relationships
 - non-hormonal contragestational agents 238
- succinylcholine 280
- sulphasalazine 266
- sulphation
 - isolated hepatocytes 102
- T**
- toxicity
 - covalent binding
 - involvement of specific coenzyme binding
 - 34, 2
 - haloalkanes
 - 4, 2
 - haloalkenes 18, 2
 - specific covalent binding and toxicity of
 - aliphatic halogenated xenobiotics 2
 - volatile anaesthetic metabolism and acute
 - toxicity 49
- tranquilizers
 - pyridoxal phosphate 306
- trans-dichloroethylene 26, 2
- triamterene 275
- triazole
 - derivatives
 - tricyclic
 - contragestational agents 238
- trichloroethane toxicity 14, 2
- trichloroethylene 27
- U**
- urinary excretion
 - altered 269
- V**
- vasodilators 276

- verapamil 274
- vinyl bromide 20, 2
- vinyl chloride 20, 2
- vinyl fluoride 20, 2
- vinylidene chloride 24, 2
- vinylidene fluoride 24, 2
- vitamin B6 290
- vitamin toxicity
 - nullification of therapeutic effects of drugs 298
- volatile anaesthetic metabolism
 - acute toxicity 49
- X**
- xenobiotic metabolism
 - species and organ differences
 - isolated hepatocytes 104
 - use of isolated hepatocytes 111
 - xenobiotic toxicity and active metabolites 109
- xenobiotics
 - aliphatic halogenated
 - specific covalent binding and toxicity 2
- Z**
- zinc
 - absorption
 - vitamin B 308

AUTHOR INDEX: Volume IV

Al-Sayegh A. 289-331
Assandri A. 237-261
Cousins MJ. 49-98
Davies R. 123-170
de la M. Hall P. 49-98
Ebadi M. 289-331
Fry JR. 99-122
Galliani G. 237-261
Gessert CF. 289-331
Gibson GG. 123-170
Johnson BF. 263-287
Laib RJ. 1-48
Lenk W. 171-236
Makowski R. 123-170
Onodei-Sale A. 237-261
Plummer JL. 49-98
Sterzl H. 171-236
Urbach DR. 263-287